Literature DB >> 9546291

Pick's disease: a modern approach.

D W Dickson1.   

Abstract

Pick's disease is a rare dementing disorder that is sometimes familial. The cardinal features are circumscribed cortical atrophy most often affecting the frontal and temporal poles and argyrophilic, round intraneuronal inclusions (Pick bodies). Clinical manifestations reflect the distribution of cortical degeneration, and personality deterioration and memory deficits are often more severe than visuospatial and apraxic disorders that are common in Alzheimer's disease, but clinical overlap with other non-Alzheimer degenerative disorders is increasingly recognized. Neuronal loss and degeneration are usually maximal in the limbic system, including hippocampus, entorhinal cortex and amygdala. Numerous Pick bodies are often present in the dentate fascia of the hippocampus. Less specific features include leukoencephalopathy and ballooned cortical neurons (Pick cells). Glial reaction is often pronounced in affected cerebral gray and white matter. Tau-immunoreactive glial inclusions are a recently recognized finding in Pick's disease, and neuritic changes have also recently been described. Variable involvement of the deep gray matter and the brainstem is typical, with a predilection for the monoaminergic nuclei and nuclei of the pontine base. Neurochemical studies demonstrate deficits in intrinsic cortical neurotransmitter systems (e.g., somatostatin), but inconsistent loss of transmitters in systems projecting to the cortex (e.g., cholinergic neurons of the basal nucleus). Biochemical and immunocytochemical studies have demonstrated that abnormal tau proteins are the major structural components of Pick bodies. A specific tau protein immunoblotting pattern different from that seen in Alzheimer's disease and certain other disorders has been suggested in some studies. A specific molecular marker and a genetic locus for familial cases are not known.

Entities:  

Mesh:

Year:  1998        PMID: 9546291     DOI: 10.1111/j.1750-3639.1998.tb00158.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  21 in total

1.  A Novel Tau Mutation in Exon 12, p.Q336H, Causes Hereditary Pick Disease.

Authors:  Pawel Tacik; Michael DeTure; Kelly M Hinkle; Wen-Lang Lin; Monica Sanchez-Contreras; Yari Carlomagno; Otto Pedraza; Rosa Rademakers; Owen A Ross; Zbigniew K Wszolek; Dennis W Dickson
Journal:  J Neuropathol Exp Neurol       Date:  2015-11       Impact factor: 3.685

Review 2.  Protein astrogliopathies in human neurodegenerative diseases and aging.

Authors:  Gabor G Kovacs; Virginia M Lee; John Q Trojanowski
Journal:  Brain Pathol       Date:  2017-09       Impact factor: 6.508

3.  Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases.

Authors:  Gabor G Kovacs; John L Robinson; Sharon X Xie; Edward B Lee; Murray Grossman; David A Wolk; David J Irwin; Dan Weintraub; Christopher F Kim; Theresa Schuck; Ahmed Yousef; Stephanie T Wagner; Eunran Suh; Vivianna M Van Deerlin; Virginia M-Y Lee; John Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  2017-04-01       Impact factor: 3.685

Review 4.  Tau tubulin kinases in proteinopathy.

Authors:  Laura M Taylor; Pamela J McMillan; Brian C Kraemer; Nicole F Liachko
Journal:  FEBS J       Date:  2019-05-22       Impact factor: 5.542

5.  Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG).

Authors:  Gabor G Kovacs; Sharon X Xie; Edward B Lee; John L Robinson; Carrie Caswell; David J Irwin; Jon B Toledo; Victoria E Johnson; Douglas H Smith; Irina Alafuzoff; Johannes Attems; Janos Bencze; Kevin F Bieniek; Eileen H Bigio; Istvan Bodi; Herbert Budka; Dennis W Dickson; Brittany N Dugger; Charles Duyckaerts; Isidro Ferrer; Shelley L Forrest; Ellen Gelpi; Stephen M Gentleman; Giorgio Giaccone; Lea T Grinberg; Glenda M Halliday; Kimmo J Hatanpaa; Patrick R Hof; Monika Hofer; Tibor Hortobágyi; James W Ironside; Andrew King; Julia Kofler; Enikö Kövari; Jillian J Kril; Seth Love; Ian R Mackenzie; Qinwen Mao; Radoslav Matej; Catriona McLean; David G Munoz; Melissa E Murray; Janna Neltner; Peter T Nelson; Diane Ritchie; Roberta D Rodriguez; Zdenek Rohan; Annemieke Rozemuller; Kenji Sakai; Christian Schultz; Danielle Seilhean; Vanessa Smith; Pawel Tacik; Hitoshi Takahashi; Masaki Takao; Dietmar Rudolf Thal; Serge Weis; Stephen B Wharton; Charles L White; John M Woulfe; Masahito Yamada; John Q Trojanowski
Journal:  J Neuropathol Exp Neurol       Date:  2017-07-01       Impact factor: 3.685

Review 6.  Tau and axonopathy in neurodegenerative disorders.

Authors:  Makoto Higuchi; Virginia M Y Lee; John Q Trojanowski
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

7.  Phosphoproteomic analysis reveals site-specific changes in GFAP and NDRG2 phosphorylation in frontotemporal lobar degeneration.

Authors:  Jeremy H Herskowitz; Nicholas T Seyfried; Duc M Duong; Qiangwei Xia; Howard D Rees; Marla Gearing; Junmin Peng; James J Lah; Allan I Levey
Journal:  J Proteome Res       Date:  2010-10-22       Impact factor: 4.466

8.  Quantitative analysis of the detergent-insoluble brain proteome in frontotemporal lobar degeneration using SILAC internal standards.

Authors:  Nicholas T Seyfried; Yair M Gozal; Laura E Donovan; Jeremy H Herskowitz; Eric B Dammer; Qiangwei Xia; Li Ku; Jianjun Chang; Duc M Duong; Howard D Rees; Deborah S Cooper; Jonathan D Glass; Marla Gearing; Malú G Tansey; James J Lah; Yue Feng; Allan I Levey; Junmin Peng
Journal:  J Proteome Res       Date:  2012-04-04       Impact factor: 4.466

Review 9.  Neuropathologic differentiation of progressive supranuclear palsy and corticobasal degeneration.

Authors:  D W Dickson
Journal:  J Neurol       Date:  1999-09       Impact factor: 4.849

Review 10.  Frontotemporal lobar degeneration: epidemiology, pathology, diagnosis and management.

Authors:  Rachel E Seltman; Brandy R Matthews
Journal:  CNS Drugs       Date:  2012-10-01       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.